OR

Oramed Pharmaceuticals IncNASDAQ ORMP Stock Report

Last reporting period 31 Dec, 2023

Updated 14 Nov, 2024

Last price

Market cap $B

0.096

Micro

Exchange

XNAS - Nasdaq

ORMP Stock Analysis

OR

Uncovered

Oramed Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.096

Dividend yield

Shares outstanding

39.784 B

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 17 full-time employees. The company went IPO on 2002-04-01. Its POD (Protein Oral Delivery) technology has been designed to protect orally delivered proteins from detrimental enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. Its pipeline includes ORMD-0801 diabetes, ORMD-0901, and ORMD-0801 non-alcoholic steatohepatitis (NASH). Its flagship product, ORMD-0801, allows insulin to travel from the gastrointestinal tract via the portal vein to the liver. The company is conducting Phase III trials in patients with type 2 diabetes. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone, that stimulates the secretion of insulin from the pancreas. The company is also engaged in the research and development of an oral vaccine for COVID-19 through its subsidiary Oravax Medical Inc.

View Section: Eyestock Rating